Despite producing pro-tumorigenic effects at low doses, high doses of progesterone have demonstrated therapeutic effects against GBM by downregulating the activity of progesterone receptor B (PR-B), a protein that promotes tumor cell growth, or through alteration of detoxification mechanisms, stress, immune response, and glucose metabolism [62,63,64,65,66,67]. This evidence concerns the gene RB1 and neoplasm.